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Previously we have found vicagrel, a new acetate derivative of clopidogrel, underwent
hydrolysis to 2-oxo-clopidogrel and subsequent conversions to its pharmacological
active metabolite (AM) and inactive carboxylic acid metabolite (CAM). This study
demonstrated the interspecies differences of the vicagrel bioactivation by comparing
the critical vicagrel metabolites formation in rats, dogs and human. The pharmacokinetic
studies with rats and dogs were conducted after intragastric administration of vicagrel,
followed by in vitro metabolism investigation in venous system, intestinal/hepatic
microsomes from rats, dogs and human. An obvious disparity was observed in
system exposure to AM (99.0 vs. 635.1 µg·h/L, p < 0.05) and CAM (10119 vs.
2634 µg·h/L, p < 0.05) in rats and dogs. It was shown that the cleavage of
vicagrel was almost completed in intestine with great different clearance (53.28 vs.
3.643 L·h−1·kg−1, p < 0.05) in rats and dogs. With no further hydrolysis to CAM,
the greatest clearance of AM (3.26 mL·h−1·kg−1) was found in dog intestine. In rat
plasma, 2-oxo-clopidogrel was much more extensively hydrolyzed to CAM than in
dog and human. Albeit similar hydrolysis clearance and AM production was observed
among hepatic microsomes of the three species, the production velocity of CAM
ranked highest in dogs (7.55 pmol/min/mg protein). Therefore, the unconformity of
AM and CAM exposure cross species mainly came from the metabolism of 2-oxo-
clopidogrel associated largely with tissue specificity and interspecies differences of
esterases. In human, the pharmacokinetics of vicagrel might be more optimistic due
to less inactivation hydrolysis before reaching liver.
Keywords: vicagrel, active metabolite, inactivation hydrolysis, esterase, CYP450s, bioactivation, species
difference
INTRODUCTION
Currently, the low-response or non-response to clopidogrel treatment in cardiovascular diseases
is of increasing concern, particularly in the condition of acute coronary syndrome (ACS) or
clopidogrel resistance (CR) (Nguyen et al., 2005; Vlachojannis et al., 2011; Qureshi and Hobson,
2013). Clopidogrel is regularly prescribed in combination with aspirin to treat ACS or prevent
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thrombotic events following percutaneous coronary intervention
(PCI) (Cooke et al., 2006). Albeit this combined therapy is
highly recommended for its efficiency on reducing the mortality,
it showed potential gastro-intestinal risk such as duodenal
ulcer and gastrointestinal bleeding caused by aspirin in the
formulation (Cooke et al., 2006). Prasugrel, a modified analog
of clopidogrel shows higher pharmacological potency due to its
rapid conversion to active metabolite (AM), which allows it to
be used as monotherapy for the treatment of ACS (Lazar and
Lincoff, 2009; Wiviott et al., 2010). However, US FDA issued
a black box warning regarding prasugrel and its side effect
of potential bleeding risk accompanied by its fast metabolite
activation (FDA, 2010; Rodriguez et al., 2013). Given the merits
and demerits of clopidogrel and prasugrel, vicagrel (Figure 1), a
novel acetate analog of clopidogrel was developed (Shan et al.,
2012) and approved by China Food and Drug Administration
(CFDA). Vicagrel, sharing the similar metabolic pattern to
prasugrel, is esterified from clopidogrel being expected to
perform improved anti-platelet efficiency and reduced bleeding
risk (Shan et al., 2012).
In preliminary pharmacological screening, vicagrel exhibits
enhanced anti-platelet aggregation potency compared to
clopidogrel and shows somewhat lower potency than prasugrel
(Shan et al., 2012). In addition, the systemic exposure of
AM produced from vicagrel was 5–6 fold higher than that from
clopidogrel according to our previous study (Qiu et al., 2013). It is
inspiring that the AM production efficiency is improved through
faster 2-oxo-clopidogrel formation from vicagrel catalyzed by
FIGURE 1 | Chemical structures and proposed metabolic pathway of vicagrel (Representative metabolites surrounded by dashed lines were not
considered in the present study; there were three competitive pathways involving 2-oxo-clopidogrel further metabolism, we mainly focused on the
critical pathway to generate AM) (Qiu et al., 2014).
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esterases including carboxylesterases (CEs) especially CE2,
paraoxonases (PON), butyrylcholineesterases (BChE) (Qiu et al.,
2014). This very rapid formation of 2-oxo-clopidogrel from
vicagrel facilitates subsequent AM production mediated by
CYP450s.
Clearly, CEs are mainly responsible for the hydrolysis of 85%
clopidogrel to the main inactive acid form, although there are
many other non-esterase hydrolysis enzymes involved in this
process (Hagihara et al., 2009; Farid et al., 2010). The inactive
hydrolysis may also happen to 2-oxo-clopidogrel (about 50%)
and AM (Zhu et al., 2013). With the same main skeleton as
clopidogrel, vicagrel could also suffer the inactivation through
its hydrolysis to carboxylic acid (Figure 1). In order to clarify
its biotransformation property, it is vital to look into the species
difference of esterases. CE1 is expressed far more abundantly
compared to CE2 in the liver of all species including rats, dogs
and human (Taketani et al., 2007; Yang et al., 2009). While
CE2 but not CE1 is predominately expressed in rat and human
intestine (Crow et al., 2007; Taketani et al., 2007). It is well
documented that there is almost no any esterase located in the
intestine of dogs (Berry et al., 2009). It is worth to point out
that rat plasma contains almost all types of esterase such as
CEs (CE1 and CE2), PON, BChE, ArE, and AChE (Satoh and
Hosokawa, 2006; Bahar et al., 2012). However, there are no
CEs existed in the plasma of dogs and human at all (Williams
et al., 2011). Based on the remarkable species differences in
esterases distribution, which may affect the metabolism and
disposition of ester compounds, the present investigation aimed
to evaluate the vicagrel disposition in rats and dogs to suggest
its possible metabolic fate in human. In the current study,
the pharmacokinetic behaviors of 2-oxo-clopidogrel, carboxylic
acid metabolite (CAM) of 2-oxo-clopidogrel, and AM in rats
and dogs following intragastric administration of vicagrel were
demonstrated. Additionally, the in vitro hydrolysis mainly
focusing on esterases was assessed in plasma, intestinal and
hepatic microsomes from rats, dogs and human. Moreover,
the CYP450s-dependent oxidation investigation was carried
out in intestinal and hepatic microsomes from rats, dogs and
human to compare the enzyme affinity and AM production
velocity. This study shed light on in vivo or in vitro pre-
systemic pharmacokinetic behaviors of vicagrel in different
species; further pre-clinical study is needed to provide a better
prediction of its metabolic fate and pharmacological response in
human.
MATERIALS AND METHODS
Chemicals and Reagents
Vicagrel (free base, 98% pure), 2-oxo-clopidogrel (99%
pure) were kindly supplied by the State Key Laboratory
of Natural Medicines and the Center of Drug Discovery,
China Pharmaceutical University, respectively. MP-AM
(AM derivatized with 3-methoxyphenacyl bromide) and
CAM of 2-oxo-clopidogrel was synthesized by the Center of
Drug Discovery, China Pharmaceutical University. Prasugrel
thiolactone metabolite (R-95913, 98% pure) was donated
by Chia-Tai Tian Qing Pharmaceutical Co. Ltd (Jiangsu,
China), and used as internal standard (ISTD) in the present
experiment. The derivatizing agent 3-methoxyphenacyl bromide
(MPBr) was purchased from TCI (Shanghai) Development
Co., Ltd. Glutathione (GSH) was bought from J&K Scientific
(Shanghai, China). Sodium carboxymethyl cellulose (CMC-
Na) was purchased from Dai-Ichi Kogyo Seiyaku Co., Ltd
(Shanghai, China). Nicotinamide adenine dinucleotide
phosphate (NADPH) regenerating system was bought from
Sigma-Aldrich (St. Louis, MO, USA). HPLC grade acetonitrile
and methanol were purchased from Tedia (Fairfield, OH,
USA). All other chemicals and agents were of analytical
grade.
Rat, Dog, and Human Intestinal and
Hepatic Microsomes
The pooled intestinal microsomes of rats [20 male Sprague-
Dawley (SD) rats] and dogs (5 male beagle dogs) were kindly
supplied by Research Institute for Liver Disease (Shanghai,
China). The human intestinal microsomes (pooled, 10
mixed gender donors) were purchased from Celsis In Vitro
Technologies (Baltimore, MD, USA). The human hepatic
microsomes (pooled, 10 male donors) were supplied by Research
Institute for Liver Disease (Shanghai, China). The rat (pooled
10 male and female SD rats) and dog (pooled 10 male and
female beagle dogs) hepatic microsomes were prepared within
lab by differential centrifugation at 9000 g at 4◦C for 20 min
and 100,000 g at 4◦C for 60 min. The protein concentration
of produced microsomes was determined by BCA protein
assay commercial kit from Shanghai Generay Biotech Co., Ltd
(Shanghai, China). The microsomes were kept at −70◦C and
thawed at 4◦C before use.
Rat, Dog and Human Plasma
Rat plasma was sampled and pooled from 10 male and female SD
rats purchased from Shanghai SIPPR/BK Experimental Animal
Co., Ltd (Shanghai, China). Dog plasma was collected and pooled
from 10 male and female beagle dogs housed in Southeast
University Laboratory Animal Center (Nanjing, China). Human
plasma (pooled, 10 mixed gender donors) was kindly offered by
Nanjing First Hospital (Nanjing, China). The plasma was stored
at−70◦C till analysis.
Experimental Animals
Sprague-Dawley rats of both sexes (200 ± 20 g) were supplied
by Shanghai SIPPR/BK Experimental Animal Co., Ltd (Shanghai,
China). Healthy adult beagle dogs of both sexes were kept in
Laboratory Animal Center of Southeast University (Nanjing,
China). The rats and dogs were housed under humanized
conditions with free access to water and food and acclimated
to the living environment (temperature: 20 ± 2◦C, relative
humidity: 50 ± 20%) for 1 week prior to experiments. Ahead
of drug administration, the rats and dogs were fasted for 12 h
with free access to water. All the experiments were conducted
under the protocol of Animal Ethics Committee of China
Pharmaceutical University.
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Pharmacokinetic Study in Rats and Dogs
As previously described (Qiu et al., 2013), vicagrel suspended
in CMC-Na solution was intragastrically administrated to rats
at 50 µmol/kg and dogs at 19.3 µmol/kg. After administration,
about 100 µL of blood was withdrawn from rat retinal venous
plexus at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, and 24 h. For
dogs, about 0.5 mL of blood was collected into heparinized
tubes via forearm vein at 0, 0.083, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8,
12, and 24 h. The blood samples were immediately centrifuged
at 12,000 g at 4◦C for 1 min. The harvested plasma was
processed by the addition of triple volume of cold acetonitrile
(containing 50 ng/mL ISTD, 5% acetic acid and 10 mM MPBr)
to avoid the possible degradation caused by plasma proteins
and derivatize AM (Qiu et al., 2013). Also, 1,4-dithio-DL-threitol
(DTT, as antioxidant) significantly increased the stability of 2-
oxo-clopidogrel (Li et al., 2015). In our study, the acidification
by acetic acid could also prevent the degradation of 2-oxo-
clopidogrel (from below 50% to above 85%) by compared to
the samples without acetic acid treatment. 2-oxo-clopidogrel
(89.3, 93.1, 99.3%) and AM (87.2, 98.1, 102.2%) remained
stable up to 12 h at 4◦C, and 15 days in −70◦C storage
with less than 15% deviation from nominal concentrations
at QC levels. The processed plasma samples were vortexed
for 3 min, placed at room temperature for 10 min, and
centrifuged at 16,000 rpm at 4◦C for 10 min. The supernatants
of prepared samples were stored at −70◦C till analysis. An
aliquot of 5 µL of the supernatant was injected for LC-MS/MS
analysis.
Pharmacokinetic Parameters of Target
Metabolites in Rats and Dogs
A non-compartmental analysis was applied to assess the
pharmacokinetic behaviors in rats or dogs. The maximum
concentration of target metabolites (Cmax) and the time to reach
maximum concentration (Tmax) were directly obtained from
the observed data. The area under the plasma concentration-
time curve from 0 to the last time point (AUC0−t) and to the
infinity (AUC0−∞) was calculated via trapezoidal rule. The
mean retention time (MRT) was also estimated. The half-
life (t1/2) was estimated via non-parametric elimination
rate constant k. The parameters were calculated using
WinNonlin (Version 6.4; Pharsight Corp., Mountain View,
CA, USA).
In order to investigate and compare the transformation
extent of AM and CAM from 2-oxo-clopidogrel in rats
and dogs after oral administration of vicagrel, a production
efficiency (E) was put forward between the system exposure
of AM or CAM and 2-oxo-clopidogrel, a good evidence
of pre-systematic formation of AM or CAM from 2-oxo-
clopidogrel.
EAM = AUC0−∞AMAUC0−∞2−oxo−clopidogrel or
ECAM = AUC0−∞CAMAUC0−∞2−oxo−clopidogrel
In vitro Metabolism of Vicagrel and
2-Oxo-clopidogrel in the Intestinal
Microsomes
The incubation was conducted in the intestinal microsomes to
study the degradation of vicagrel or 2-oxo-clopidogrel in the
intestine. The protein concentrations of intestinal microsomes
were set at 20, 50, and 50 µg protein/ml for vicagrel hydrolysis
in rats, dogs and human, respectively. The reaction mixtures
was pre-incubated with proteins in Tris buffer (pH 7.4, 50 mM)
at 37◦C, and initiated by the addition of vicagrel with a final
concentration at 10 µM. The reactions were terminated at 0, 1,
2, 5, 10, 20, 30, 60, 90, and 120 min by adding double volume of
cold acetonitrile (containing 50 ng/ml ISTD and 5% acetic acid).
In order to investigate the contribution of CYP450s in the
intestine to 2-oxo-clopidogrel cleavage, the incubation mixtures
contained intestinal microsomes, MgCl2 (5 mM), NADPH
(5 mM), GSH (10 mM), and the reaction was initiated at 37◦C by
adding 2-oxo-clopidogrel with a final concentration at 10 µM. At
0, 5, 10, 20, 30, 60, 90, and 120 min, the reaction was stopped and
the samples were derivatized as described above. The intestinal
protein concentration was all set at 1 mg/ml for rats, dogs
and human. The added GSH was to generate and stabilize AM
(2-oxo-clopidogrel is converted to a sulfenic acid intermediate,
which is further reduced by GSH to open the thiolactone ring to
produce a GSH conjugate, then to yield AM by a thiol-disulfide
exchange) (Zhang et al., 2012, 2013). Meanwhile, the contribution
of intestinal CYP450s-mediated metabolism was assessed by the
reaction with or without the presence of NADPH.
In vitro Hydrolysis of 2-Oxo-clopidogrel
in Plasma
Before the in vitro hydrolysis assay, plasma was centrifuged at
3000 rpm for 10 min at 4◦C, and the supernatant was adjusted
to pH 7.4 using Tris buffer (pH 7.4, 0.05 M). For the subsequent
hydrolysis of 2-oxo-clopidogrel, the plasma volume was 0.1, 10,
and 10% of the total incubation volume for rats, dogs, and
human, respectively. The reaction was terminated at 0, 2, 5, 10,
20, 30, 60, 90, and 120 min as described above. Then the sample
was processed for analysis.
In vitro Metabolism of 2-Oxo-clopidogrel
in the Hepatic Microsomes
Initially, the hydrolytic reaction was carried out with hepatic
microsomes to assess the degradation of 2-oxo-clopidogrel
without the cofactor NADPH. The protein concentrations of
hepatic microsomes were 0.5, 0.5 and 0.2 mg/ml for rats, dogs
and human, respectively. The incubation mixtures was pre-
incubated in Tris buffer (pH 7.4, 50 mM) at 37◦C, and initiated by
addition of 2-oxo-clopidogrel (final concentration at 10µM). The
reactions were terminated at 0, 5, 10, 20, 30, 60, 90, and 120 min
as described above. For the system of AM production, the
mixtures contained protein (1 mg/ml for rats and dogs, 0.5 mg/ml
for human), MgCl2, NADPH, GSH, and the incubations were
initiated by adding of 2-oxo-clopidogrel (final concentration at
10 µM). At 0, 5, 10, 20, 30, 60, 90, and 120 min, the reaction was
stopped and derivatized as above method.
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In vitro-In vivo Extrapolation
In the in vitro hydrolysis or NADPH-mediated oxidation
experiments, the incubation time and protein amounts were
varied among species and organs. In order to compare the
metabolic profiles of vicagrel or 2-oxo-clopidogrel among rats,
dogs and human, we introduced the in vitro clearance, Clin vitro
by scaled in organ level or the whole body in terms of kinetics,
which were estimated by the following equation:
C1in vitro = 0.693t1/2 (
−1
min)× Vincubation(ml)
Pr otein(mg protein)
Where t1/2 was the half-life estimated from the elimination rate
constant λ of vicagrel or 2-oxo-clopidogrel in plasma, intestinal
and hepatic microsomes from rats, dogs or human. Protein
was the protein concentration of plasma, intestinal or hepatic
microsomes in the incubation system. V was the total volume
of the incubation system. Afterward, the Clin vitro was scaled
to intrinsic clearance (Clint) by introducing the scaling factors,
calculated as follows:
C1int = C1in vitro × Pr otein(mg protein)Tissue(g) ×
Tissue(g)
Body weight(kg)
Tissue represented the weight of intestine or liver, or plasma
volume, where the intestine weight was set at 4, 220, 700 g
(Karlsson et al., 2013), and liver weight was 10, 320, and 1800 g
for rats, dogs and human respectively (Davies and Morris, 1993).
The volume of plasma in rats, dogs and human was referred as
7.8, 515, 3000 ml, respectively. The microsomal protein yield ratio
was 3 mg/g for intestine and 45 mg/g for liver (Obach et al., 1997;
Paine et al., 1997; Yang et al., 2007). The plasma total protein was
set at 65, 58, and 78 mg protein per plasma unit for rats, dogs
and human, respectively (Tibbitts, 2003). The other parameters
referred to physiological parameters in lab in laboratory rats, dogs
and human.
AM Formation Kinetics Assay in the
Intestinal and Hepatic Microsomes
For AM production, the triplicate reaction mixture consisted of
Tris buffer (pH 7.4, 50 mM), 5 mM NADPH, 5 mM MgCl2, 5 mM
GSH, human, dog, or rat intestinal or hepatic microsomes. The
substrate concentration of 2-oxo-clopidogrel was set at 0.5, 1, 2,
5, 10, 20, 50, and 100 µM. The final protein concentrations of
microsomes were optimized as 1.0 and 0.5 mg protein/ml, and
the incubation time was set at 60 min and 30 min for intestinal
and hepatic microsomes, respectively. After the incubation, the
reaction was terminated by the addition of cold acetonitrile
containing ISTD and derivatization reagent.
The production pattern in the intestinal and hepatic
microsomes was fitted to Michaelis–Menten equation shown
as below. Meanwhile, the profile of productive velocity versus
substrate was transformed via Eadie–Hofstee plot.
v = vmax × S
Km + S (Michaelis−Menten equation)
Where v was the formation velocity of AM, expressed as
pmol/min/mg protein, likewise, Vmax was the maximum
formation velocity, S presented the substrate concentration,
Km was the Michaelis constant, represented the substrate
concentration when the reaction velocity reaching the half of
Vmax, also, K represented the enzyme affinity to substrate. The
Eadie-Hofstee plot was used to evaluate the authentic AM
formation kinetics whether the formation exhibited monophasic
or not. The data was handled by Graphpad Prism 5.0. The
in vitro clearance and intrinsic clearance of 2-oxo-clopidogrel
to AM were introduced to evaluate the contributions of CYP-
based oxidation to AM from 2-oxo-clopidogrel, where Clin vitro
was calculated as Clin vitro = vmaxKm , and the intrinsic clearance was
scaled using in vitro t1/2 approach.
LC-MS/MS Analysis
Vicagrel, 2-oxo-clopidogrel, CAM, AM and ISTD were analyzed
via LC-MS/MS analysis according to our previous report (Qiu
et al., 2013). Specifically, the analysis used an API4000 MS
system and Shimadzu HPLC system. The analytes were separated
via gradient elution on Shimadzu VP-ODS column, and then
flowed with mobile phase to MS system to conduct MRM
(multiple reaction monitoring) scan. The column temperature
was set at 30◦C. The transition conditions of specific analyte
were optimized. Vicagrel, 2-oxo-clopidogrel, CAM, AM-MPBr
(AM was derivatized by MPBr), as well as ISTD were monitored
as m/z 380.1 to m/z 212.1, m/z 338.2 to m/z 155.1, m/z
324 to m/z 169.2, m/z 504.0 to m/z 212.1, and 332.1 to m/z
149.1, respectively. The declustering potential was set at 45.0,
45.0, 53.1, 36.5, and 45.0 v, respectively, and the collision
energy at 35, 35, 38.1, 25.4 and 35 ev, respectively. Each run
was 7.5 min. Meanwhile, the quality control samples were
analyzed to ensure the accuracy and precision of analytical
method.
Statistical Analysis
All data were represented as the means ± SEM. Statistical
analysis was calculated by a one-way ANOVA with Newman–
Keuls test. The acceptable level of significance was established at
p < 0.05.
RESULTS
Pharmacokinetics of Target Metabolites
of Vicagrel in Rats and Dogs
Following intragastric administration to rats or dogs, vicagrel
was rapidly transformed to 2-oxo-clopidogrel, AM and CAM
(Figure 2). In rats and dogs, 2-oxo-clopidogrel reached each
Cmax within 0.45 ± 0.23 and 0.61 ± 0.32 h, respectively, and
the AUC0−∞ of 2-oxo-clopidogrel in dogs was about two-
fold higher than that in rats. AM exhibited shorter peak time
(0.16 ± 0.09 h) and higher Cmax (713.1 ± 332.5 µg/L) in dogs,
compared to those in rats (0.67 ± 0.24 h, 39.7 ± 23.2 µg/L).
Correspondingly, the system exposure to AM was much
higher in dogs (716.5 ± 238.5 µg·h/L) than that in rats
(64.2± 24.2 µg·h/L). The EAM (production efficiency) was about
1.2 in rats and 6.5 in dogs. The CAM in rat peaks at 0.50± 0.27 h
Frontiers in Pharmacology | www.frontiersin.org 5 October 2016 | Volume 7 | Article 366
fphar-07-00366 October 7, 2016 Time: 11:36 # 6
Qiu et al. Pre-systemic Bioactivation of Vicagrel in Species
FIGURE 2 | Plasma concentration-time profiles of 2-oxo-clopidogrel (A), AM (B) and carboxylic acid metabolite (C) in dogs (19.4 µmol/kg, n = 5) and
rats (50 µmol/kg, n = 5) following intragastric administration of vicagrel. (The line marked in red represented the profiles in dog).
TABLE 1 | Pharmacokinetic parameters of 2-oxo-clopidogrel, AM and CAM following intragastric administration of vicagrel at 50 µmol/kg to rats (n = 6)
and 19.4 µmol/kg to dogs (n = 6).
2-Oxo-clopidogrel AM CAM
Rats Dogs Rats Dogs Rats Dogs
Cmax(µg/L) 22.6 ± 9.79 64.8 ± 8.04∗ 39.7 ± 23.2 713.1 ± 332.5∗ 372.9 ± 96.84 5676.6 ± 388.7∗
Tmax(h) 0.45 ± 0.23 0.61 ± 0.32 0.67 ± 0.24 0.16 ± 0.09 ∗ 0.50 ± 0.27 0.35 ± 0.14
AUC0−t(µg·h/L) 47.9 ± 15.8 109.8 ± 50.3∗ 62.0 ± 23.8 711.9 ± 239.1∗ 2634 ± 568.9 10119 ± 1193.6∗
AUC0−∞(µg·h/L) 51.8 ± 17.1 110.2 ± 50.4∗ 64.2 ± 24.2 716.5 ± 238.5∗ 3080 ± 641.9 10163 ± 1179.4∗
MRT0−t(h) 3.45 ± 0.46 1.33 ± 0.45∗ 1.96 ± 0.45 0.97 ± 0.09∗ 7.47 ± 1.21 1.69 ± 0.27∗
t1/2(h) 3.32 ± 0.93 0.84 ± 0.42∗ 1.85 ± 1.17 1.19 ± 0.28∗ 8.86 ± 1.23 4.97 ± 0.97∗
∗p < 0.05, rat vs. dog.
with Cmax at 372.9 ± 96.84 µg/L, while that in dog peaks at
0.35 ± 0.14 h with Cmax at 5676.6 ± 388.7 µg/L. The AUC0−∞
of CAM was 3080 ± 641.9 µg·h/L with an estimated half-life of
8.86± 1.23 h in rats. Surprisingly, AUC0−∞ of CAM in dogs were
much higher, calculated at 10163 ± 1179.4 µg·h/L. Additionally,
it was cleaved more rapidly with a half-life of 4.97 ± 0.97 h. And
the ECAM was calculated as 59.5 in rats and 92.2 in dogs (Table 1).
Hydrolysis of Vicagrel and
2-Oxo-clopidogrel in the Intestinal
Microsomes
After the initiation of hydrolysis, vicagrel was rapidly hydrolyzed
in the intestinal fractions (Figure 3A). In rat and human
intestinal microsomes, the 2-oxo-clopidogrel was produced
immediately from vicagrel and peaked around at 5–10 min with
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FIGURE 3 | The degradation profiles of vicagrel (A), 2-oxo-clopidogrel (B) and production profiles of 2-oxo-clopidogrel from vicagrel (C) in the
intestinal microsomes from rat, dog and human (The reactions were conducted in pH 7.4 Tris buffer at 37◦C and initiated by the addition of vicagrel
with a final concentration at 10 µM; The line marked in red represented the profiles in dog).
almost complete conversion (the observed response under initial
condition without incubation was treated as control). While in
dog intestinal microsomes, the amount of 2-oxo-clopidogrel was
gradually increased upon the incubation time with complete
cleavage from vicagrel at approximate 30 min (Figure 3B). The
degradation half-life of vicagrel in the intestinal microsomes from
rats, dogs and human were estimated as 2.4 ± 0.2, 15.3 ± 2.6
and 1.6 ± 0.7 min, respectively. The scaled Clint was highest in
rats (53.28 L·h−1·kg−1), and lowest in dogs (3.643 L·h−1·kg−1).
It is evidenced that the spiked 2-oxo-clopidogrel in the same
incubation systems was relatively stable in the absence of NADPH
(Figure 3C, Table 2), which was in exceptional agreement with
the below results that there was no CAM generated in the
intestinal microsomes from rats, dogs or human, probably due
to the lack of CE1 expression in the intestine of the three
species.
Hydrolysis of 2-Oxo-clopidogrel in
Plasma
In plasma, 2-oxo-clopidogrel was degraded with the
elimination half-life of 66.4 ± 14.0, 134.6 ± 16.9 and
127.1± 16.3 min in rats, dogs and human, respectively (Table 3).
Correspondingly, the scaled Clint ranked the highest in rat
TABLE 2 | Intestinal hydrolysis of vicagrel and 2-oxo-clopidogrel in the intestinal microsomes from rats, dogs, and human.
λ (min−1) t1/2 (min−1) Clin vitro (L·h−1·g protein−1) Clint (L·h−1·kg−1)
Vicagrel
Rat 0.296 ± 0.020 2.4 ± 0.2 888.0 ± 60.00 53.28 ± 3.600
Dog 0.046 ± 0.007∗ 15.3 ± 2.6∗ 55.20 ± 8.651∗ 3.643 ± 0.571∗
Human 0.439 ± 0.020 1.6 ± 0.7 526.8 ± 24.00 15.80 ± 0.720
2-oxo-clopidogrel
Rat 0.0023 ± 0.000 – – –
Dog 0.0030 ± 0.001 – – –
Human 0.0018 ± 0.003 – – –
–The parameters were not calculated, since the elimination rate constants of 2-oxo-clopidogrel in the intestinal microsomes without NADPH were restricted within quite
small extent. ∗p < 0.05, dog vs. rat or human.
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plasma (0.182 L·h−1·kg−1), followed by dog (0.075 L·h−1·kg−1)
and human (0.053 L·h−1·kg−1).
Besides, only in rat plasma CAM was extensively produced,
and the formation was dose-dependent with 11.05 and
34.65 pmol/min/mg protein at 5 and 50 µM (Table 5).
Hydrolysis of 2-Oxo-clopidogrel in
Hepatic Microsomes
The degradation half-life of 2-oxo-clopidogrel in rat, dog, and
human hepatic microsomes was 1.09 ± 0.06, 1.34 ± 0.09 and
2.88 ± 0.42 h−1, respectively, and the scaled intrinsic Clint
was 2.304 ± 0.125, 1.498 ± 0.100 and 1.412 ± 0.209 L/h/kg,
respectively (Table 4).
Carboxylic acid metabolite was extensively generated from
2-oxo-clopidogrel in hepatic microsomes in the absence of
NADPH. The dog hepatic microsomes exhibited the greatest
production rate, while rats ranked the lowest among the three
species. At 5 µM of 2-oxo-clopidogrel, the CAM production
rates were calculated at around 1.78, 7.55 and 4.14 pmol/min/mg
protein for rats, dogs, and human, respectively (Table 5).
AM Formation Kinetics in the Intestinal
and Hepatic Microsomes
The well fitted Eadie–Hofstee plots indicated the classic
Michaelis-Menten pattern of AM production from 2-oxo-
clopidogrel in the presence of NADPH in the intestinal or
hepatic microsomes (Figures 4 and 5). AM was produced
with the Michaelis–Menten rate constant (Km) of 14.57, 3.023
and 4.661 µM in intestinal microsomes, and 40.71, 9.392
and 17.58 µM in hepatic microsomes of rats, dogs and
human, respectively. The dog’s intestine exhibited the highest
intrinsic clearance from 2-oxo-clopidogrel to AM, estimated as
3.26 ml·h−1·kg−1. However, there was no significant difference
in the hepatic clearance among rats, dogs, and human (Table 6).
DISCUSSION
For clopidogrel, the CYP450-mediated activation to AM is a
quantitatively minor metabolic pathway. Parallelly, the majority
of clopidogrel is hydrolyzed to clopidogrel CAM, which
is subsequently conjugated to clopidogrel acyl glucuronide
mediated by β-glucuronidase (Savu et al., 2016). Vicagrel
experiences several metabolic fates in vivo. It bypasses the first-
step of thiolactone metabolite production mediated by CYP1A2,
2C9, 2C19, and 3A4 (Kazui et al., 2010) that are responsible
for 2-oxo-clopidogrel production from clopidogrel. Instead, it is
converted to 2-oxo-clopidogrel mainly by esterases such as CEs,
PON and BChE, guaranteeing the enhanced rate and capacity
of 2-oxo-clopidogrel and subsequent AM formation (Qiu et al.,
2014). The 2-oxo-clopidogrel is further cleaved to CAM mainly
mediated by CE1 (Zhu et al., 2013), which is a parallel metabolic
pathway to the AM production mediated by CYP3A4, 2B6, 2C19,
TABLE 3 | Plasma hydrolysis of 2-oxo-clopidogrel in rats, dogs, and human.
λ (min−1) t1/2 (min−1) Clin vitro (L·h−1·g protein−1) Clint (L·h−1·kg−1)
Rat 0.011 ± 0.0019 66.4 ± 14.0∗ 0.101 ± 0.019∗ 0.182 ± 0.034∗
Dog 0.0052 ± 0.0012 134.6 ± 16.9 0.052 ± 0.010 0.075 ± 0.014
Human 0.0063 ± 0.0011 127.1 ± 16.3 0.046 ± 0.008 0.053 ± 0.009
∗p < 0.05, rat vs. dog or human.
TABLE 4 | Hepatic Hydrolysis of 2-oxo-clopidogrel in hepatic microsomes from rats, dogs and human.
λ (h−1) t1/2 (h−1) Clin vitro (L·h−1·g protein−1) Clint (L·h−1·kg−1)
Rat 0.640 ± 0.035 1.09 ± 0.06∗ 1.280 ± 0.069 2.304 ± 0.125
Dog 0.520 ± 0.035 1.34 ± 0.09 1.036 ± 0.066 1.498 ± 0.100
Human 0.244 ± 0.036 2.88 ± 0.42 1.220 ± 0.181 1.412 ± 0.209
∗p < 0.05, rat vs. dog or human.
TABLE 5 | The production velocity of CAM from 2-oxo-clopidogrel in the plasma, intestinal and hepatic microsomes from rats, dogs, and human.
Rats Dogs Human
Production velocity (pmol/min/mg protein)
Intestine 5 µM – – –
50 µM – – –
Plasma 5 µM 11.05 ± 0.55 – –
50 µM 34.65 ± 0.68 – –
Liver 5 µM 1.78 ± 0.63 7.55 ± 0.68∗ 4.14 ± 0.78
50 µM 35.13 ± 3.34 67.13 ± 7.56∗ 43.88 ± 2.56
–The parameters were not calculated, because there was no CAM produced in the plasma of dogs or human, or the intestinal microsomes of rats, dogs and human.
∗p < 0.05, rat vs. dog.
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FIGURE 4 | Formation kinetics of AM in the intestinal microsomes from rat (A), dog (B), and human (C). The inset figures depicted the Eadie–Hofstee plots
of AM (The reactions were performed in pH 7.4 Tris buffer at 37◦C; the incubation time was set at 60 min).
and 2C9 (Zhu and Zhou, 2013). Similarly, both vicagrel and
AM are also possibly hydrolyzed to their acid forms (Dansette
et al., 2012), which presumed to be neglected in the present study
(Figure 1). Moreover, the generation of AM is an important and
direct indicator to distinguish vicagrel and clopidogrel. Hence, 2-
oxo-clopidogrel (the most important intermediate metabolite of
vicagrel), CAM (the main inactive metabolite of vicagrel) and AM
(pharmacological AM) were used as the target metabolites in this
article to investigate the disposition of vicagrel in animal species
and to suggest its possible metabolic fate in human.
The in vivo data showed that the system exposure and
transformation efficiency of CAM and AM were both higher
in dogs than in rats. However, the duration of CAM retained
in rats was dramatically longer than in dogs (MRT 7.47 vs.
1.69 h). Moreover, the AM in dogs was eliminated with a much
shorter half-life (Qiu et al., 2013). Thus, the production rather
than elimination was the determinant of vicagrel transformation
efficiency to AM or CAM in dogs and rats. The further
transformation investigation was conducted with comprehensive
in vitro methods, including the intestinal, hepatic and even pre-
hepatic venous system in rats, dogs and human, to clarify the
difference of target metabolites production efficiency.
In the cellular absorption assay, vicagrel was found to be
linearly absorbed in a time- and dose-dependent manner with
passive diffusion as the major absorption pattern (within lab
data). Our results indicated that the absorption of vicagrel had
little impact on the production rates of AM and CAM. Instead,
the intestinal and hepatic metabolism of vicagrel might play a
vital role in the differential biotransformation among species.
In spite of the almost quantitatively conversions in all three
species, vicagrel was immediately hydrolyzed to its thiolactone
metabolite in rat and human intestinal microsomes, rather
than in a progressive manner as in dogs. The difference
in conversion rates was mainly attributed to the localization
and expression pattern of esterases or esterase-like enzymes
in the intestine (Qiu et al., 2014). Our previous findings
showed that the intestinal CE2 in rats and human responsible
for the rapid production of 2-oxo-clopidogrel, exhibited high
competence in vicagrel hydrolysis compared to CE1 (Satoh
and Hosokawa, 2006; Qiu et al., 2014). While for dogs, there
are no esterases identified in the intestine (Berry et al., 2009).
Hence, there might be other unidentified proteins in canine
intestine involved in the process of vicagrel hydrolysis that
works slowly but almost completely. Encouragingly, the clearance
pattern of vicagrel to 2-oxo-clopidogrel was in accordance
with the production of thiolactone intermediate (R-95913) from
prasugrel in the intestine (Hagihara et al., 2010, 2011). Thus,
the impact of intestinal esterases differences between species
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FIGURE 5 | Formation kinetics of AM in the hepatic microsomes from rat (A), dog (B), and human (C). The inset figures depicted the Eadie–Hofstee plots of
AM (The reactions were performed in pH 7.4 Tris buffer at 37◦C; the incubation time was set at 30 min).
on vicagrel hydrolysis to 2-oxo-clopidogrel is not of much
significance.
It is widely recognized that clopidogrel is converted to 2-
oxo-clopidogrel, AM, CAM and other metabolites prior to
reaching the systemic circulation. In the intestine of rats, dogs
and human, there is no convincing evidence to support the
existence of CE1 involved in the hydrolysis of 2-oxo-clopidogrel
to inactive CAM. This may provide an explanation for stable
2-oxo-clopidogrel concentrations during the incubation with
intestinal microsomes in the absence of NADPH. After the
addition of NADPH, 2-oxo-clopidogrel was converted to AM
with high affinity but low capacity, which fit well to the
classical Michaelis–Menten kinetic model, suggesting the critical
involvement of CYP450s in the intestinal clearance of 2-oxo-
clopidogrel. Compared to rats, the intestine microsomal enzymes
in dogs and human exhibited similar or even higher affinity
to this conversion. The intrinsic clearance indicated that AM
formation from vicagrel in the human showed no significant
difference from that in the rats, but it was significantly less
than that in dog (p < 0.05). These results indicated that the
AM production profile in the human intestine might resemble
that in rat when following oral administration. This indication
was consistent with the previous finding that human and rat
shares similar location and abundance of esterases (CE2) and
TABLE 6 | Kinetics of AM production from 2-oxo-clopidogrel in the intestinal and hepatic microsomes from rats, dogs, and human.
Intestine Km (µM) Vmax (pmol/min/mg protein) Clin vitro (ml·h−1·g protein−1) Clint (ml·h−1·kg−1)
Rat 14.57 ± 1.242 3.102 ± 0.08735 12.77 ± 1.039 0.766 ± 0.0623
Dog 3.023 ± 0.3466 2.489 ± 0.1154 49.40 ± 15.68∗ 3.26 ± 1.034∗
Human 4.661 ± 1.436 1.344 ± 0.1179 17.30 ± 4.414 0.571 ± 0.132
Liver Km (µM) Vmax (pmol/min/mg protein) Clin vitro (L·h−1·g protein−1) Clint (L·h−1·kg−1)
Rat 40.71 ± 4.510 203.4 ± 7.241 0.270 ± 0.0136 0.486 ± 0.025
Dog 9.392 ± 1.194 48.68 ± 1.842 0.315 ± 0.0399 0.453 ± 0.058
Human 17.58 ± 3.294 66.29 ± 2.494 0.233 ± 0.0489 0.269 ± 0.058
∗p < 0.05, dog vs. rat or human.
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CYP450s (mainly CYP3A) (Martignoni et al., 2006; Taketani
et al., 2007).
Once arriving at mesenteric vein, the metabolism of 2-oxo-
clopidogrel and AM took place in the blood pool prior to the
hepatic portal vein. It’s worth mentioning that there was no
vicagrel found in the rat portal vein or in dog circulation system,
further showing the complete conversion of vicagrel prior to
its arrival to the liver in rats or the circulation in dogs (Qiu
et al., 2013, 2014), so the metabolism of vicagrel missing from
the intestine was also negligible. Therefore, species differences in
the types and levels of esterases in plasma resulted in different
patterns of the 2-oxo-clopidogrel hydrolysis. Rat plasma contains
the most ubiquitously located esterases, including CEs (CE1 &
CE2), PON (mainly PON1), BChE, AChE, ArE, etc. And the
plasma of human and dog share similar profile of these enzymes,
including PON, BChE, AChE but no CEs (Bahar et al., 2012). The
CE1 in rat plasma was responsible for the further hydrolysis of
2-oxo-clopidogrel and AM to their carboxylic acid forms (Zhu
et al., 2013). This result was in consistence with the subsequent
observations that CE1 in rat plasma could play a pivotal role in
the formation of CAM from 2-oxo-clopidogrel and hydrolytic
loss of produced AM during absorption process (no quantitative
data), while the hydrolysis was limited in dogs or human
plasma due to the absence of CE expression. Consequently, the
presence of all 2-oxo-clopidogrel, AM, and CAM was found
in rat plasma, while dog and human plasma contained only
2-oxo-clopidogrel and AM but no CAM before reaching the liver,
which may indicate that the portion of 2-oxo-clopidogrel arriving
at dog and human liver overweighed that of rats. Moreover,
it is worth noting that 2-oxo-clopidogrel was oxidized to AM
via intestinal CYP450s with higher substrate affinity in the dog
intestine, indicating 2-oxo-clopidogrel were converted to AM
more completely in dog intestine and experienced no further
hydrolysis in dog plasma, which could be a plausible explanation
for the higher system exposure and transformation efficiency of
AM in dogs observed in vivo.
As the most important metabolic organ, liver contains
the most abundant esterases (CEs mainly CE1, PON, BChE,
AchE), CYP450s and other related enzymes with high activities
(Martignoni et al., 2006) (18). When reaching to the liver, 2-oxo-
clopidogrel and AM must be extensively metabolized. Whereby
2-oxo-clopidogrel experienced extensive hydrolysis to CAM and
oxidation to AM. The formation velocity of CAM varied among
the three species with the largest velocity was found in dog hepatic
microsomes. For the AM production, although the substrate-
enzyme affinity in dogs was comparable to that in human and
much higher than that in rats, there was no obvious difference
in the clearance of 2-oxo-clopidogrel to AM among rats, dogs,
and human. Furthermore, hepatic metabolism profiles of 2-oxo-
clopidogrel and AM in human and dogs resembled each other
as characterized by similar total clearance of 2-oxo-clopidogrel
regardless of the presence of NADPH (Tables 4 and 6).
Although the produced 2-oxo-clopidogrel and AM
encountered further hydrolysis to their carboxylic acid forms,
there was no significant difference in 2-oxo-clopidogrel cleavage
to AM between rats and dogs in the liver. In the rats, the loss of 2-
oxo-clopidogrel in the plasma further led to the reduced amount
of 2-oxo-clopidogrel in the liver, which eventually resulted in the
low production of AM and CAM in rats compared to dogs. While
in the dogs, the higher AM exposure was associated with the
higher intestinal production followed by lower loss in the plasma,
and the greater CAM production was related to lower hydrolysis
loss of 2-oxo-clopidogrel in the blood prior to the hepatic portal
vein and the higher production in the liver. Moreover, the acid
forms of vicagrel, 2-oxo-clopidogrel and AM could probably
undergo glucuronidation as occurred in clopidogrel metabolism
(Savu et al., 2016), which would be performed in following study.
CONCLUSION
In summary, our present study focused on the pre-systemic
bioactivation of vicagrel in the intestinal, hepatic as well as pre-
hepatic venous system in species in vivo and in vitro. After PO
administration to rats and dogs, vicagrel rapidly and completely
converted to 2-oxo-clopidogrel in the intestine, and subsequently
oxidized to AM via intestinal and hepatic CYP450s. In rats, the
produced 2-oxo-clopidogrel and AM in the intestine experienced
hydrolysis to inactive acid metabolites in pre-hepatic venous
system, which did not take place in dogs, and eventually led to the
differences in the exposure of AM and CAM between species. It
was reasonable to extrapolate that in human, vicagrel might share
a similar metabolic fate in the intestine with that in rats, followed
by analogous metabolic deposition of that in dog plasma and
liver. Given the metabolic pattern of the thiolactone metabolite in
dogs, vicagrel was expected to have the potential to show a more
ideal pharmacokinetic behavior with higher systemic exposure of
AM and a better pharmacological properties with faster onset of
anti-platelet aggregation in human.
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